Innsbruck Medical University

Researchers

• AFAlessandra Fanciulli

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Fiber-Optic Navigation During TIPS Creation: A Prospective Pilot Study

  NCT07470515· Medical University Innsbruck· Source

• Not yet recruiting

  Real-World Data Collection of GORE Devices Used In the Endovascular Treatment of Aortic Aneurysms Which Incorporate Visceral Arteries.

  NCT07480395· W.L.Gore & Associates· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor

  NCT07557147· Bayer· Source

• Recruiting

  Bone Deterioration After Kidney Transplantation Assessed by DXA and HR-pQCT

  NCT07935915· Medical University Innsbruck· Source

• Recruiting

  A Study of DS-3939a in Participants With Solid Tumors

  NCT07739966· Phase 1/2· Daiichi Sankyo· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Recruiting

  Cardiovascular Rehabilitation After Infrarenal Aortic Aneurysm Repair

  NCT07690046· Medical University Innsbruck· Source

• Not yet recruiting

  CHIP in Health and Disease

  NCT07780552· VASCage GmbH· Source

• Recruiting

  ROSY-F: Roll-over Study for Participants Who Have Completed a Previous Clinical Study with Benralizumab (Fasenra) and Benefit from Continued Treatment

  2025-523307-29-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  ABCSG R07 Rectal Cancer Registry

  NCT07780305· Austrian Breast & Colorectal Cancer Study Group· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  2025-524711-36-00· Phase 3· Alkermes Inc.· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

  2025-523912-35-00· Phase 3· Alkermes Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  2025-523911-13-00· Phase 3· Alkermes Inc.· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Socio-cognitive and Biological Responses to Maltreatment

  NCT07101107· Medical University Innsbruck· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· AbbVie· Source

• Recruiting

  Digital Screening for Atrial Fibrillation to Prevent Stroke

  NCT07684053· Medical University Innsbruck· Source

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source

• Recruiting

  Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction

  NCT07615023· Medical University Innsbruck· Source

• Enrolling by invitation

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source

• Not yet recruiting

  DIRECTION Study

  2025-524495-39-00· Phase 4· Medical University Of Vienna· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

  NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe

  NCT07585890· University Medical Center Groningen· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Genmab· Source

• Not yet recruiting

  Digital Application for Stroke Health

  NCT07511868· VASCage GmbH· Source

• Not yet recruiting

  Tonic Motor Activation (TOMAC) Therapy in Patients With Restless Legs Syndrome and Dopaminergic Augmentation

  NCT07397247· Noctrix Health, Inc.· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Austrian PBC Registry

  NCT07598669· Medical University of Vienna· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Telemedically Assisted Optimization for Heart Failure Patients Before Cardiac Surgery to Improve Perioperative Outcome

  NCT07391683· Medical University Innsbruck· Source

• Recruiting

  Neoadjuvant Darovasertib in Primary Uveal Melanoma

  NCT07015190· Phase 3· IDEAYA Biosciences· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Sanofi· Source

• Recruiting

  A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  NCT07253285· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  LETHE-AT: a Personalized Multidomain Lifestyle Intervention for Individuals at Increased Risk of Memory Impairment.

  NCT07376135· Medical University of Vienna· Source

• Recruiting

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

  NCT07280585· Phase 3· University of Cologne· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· GlaxoSmithKline· Source

Showing 50 of 287.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers18 recruiting
• Lung cancer11 recruiting
• Coronary artery disease8 recruiting
• Ovarian cancer8 recruiting
• Crohn's disease7 recruiting
• Parkinson disease7 recruiting
• Stroke7 recruiting
• Endometrial cancer5 recruiting
• Bladder cancer4 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Heart failure4 recruiting
• Metastatic breast cancer4 recruiting
• Multiple myeloma4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Sarcoma4 recruiting
• Ulcerative colitis4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Acute myeloid leukaemia3 recruiting
• Amyloidosis3 recruiting
• Aortic stenosis3 recruiting
• Epilepsy3 recruiting
• Glioblastoma3 recruiting
• Liver and biliary tract cancer3 recruiting
• Liver cirrhosis3 recruiting
• Macular degeneration3 recruiting
• Multiple system atrophy3 recruiting
• Narcolepsy3 recruiting
• Obesity3 recruiting
• Prostate cancer3 recruiting
• Alzheimer disease2 recruiting
• Aortic aneurysm2 recruiting
• Atrial fibrillation2 recruiting
• Bronchiectasis2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Friedreich ataxia2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Head and neck cancer2 recruiting
• High blood pressure2 recruiting
• Melanoma2 recruiting
• Multiple sclerosis2 recruiting
• Pancreatic cancer2 recruiting
• Polycystic kidney disease2 recruiting
• Restless legs syndrome2 recruiting
• Schizophrenia2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• ANCA-associated vasculitis1 recruiting
• Asthma1 recruiting
• Bipolar disorder1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic rhinosinusitis with nasal polyps1 recruiting
• Coeliac disease1 recruiting
• Colorectal cancer1 recruiting
• COPD1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Depression1 recruiting
• Follicular lymphoma1 recruiting
• Haemophilia1 recruiting
• Hearing loss1 recruiting
• Hidradenitis suppurativa1 recruiting
• Huntington's disease1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Long COVID and ME/CFS1 recruiting
• Meningioma1 recruiting
• Mild cognitive impairment1 recruiting
• Mitochondrial disease1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myocarditis1 recruiting
• Neuroblastoma1 recruiting
• Osteoporosis1 recruiting
• Peripheral artery disease1 recruiting
• Postural tachycardia syndrome (POTS)1 recruiting
• Primary biliary cholangitis1 recruiting
• Rheumatoid arthritis1 recruiting
• Spinal cord injury1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 1 diabetes1 recruiting
• Vitiligo1 recruiting

Closed trials

• Withdrawn

  A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

  NCT07084831· Phase 3· European Group for Research In Schizophrenia· Source

• Withdrawn

  Development of Digital Biomarkers in Multiple Sclerosis: Validation Study 2

  NCT06309173· Research Center for Clinical Neuroimmunology and Neuroscience Basel· Source

• Active, not recruiting

  Silexan® in mild to moderate major depressive disorder

  2025-521744-37-00· Phase 3· Dr. Willmar Schwabe GmbH & Co. KG· Source

• Recruiting

  A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

  NCT07220564· Phase 1· Novo Nordisk A/S· Source

• Completed

  Crystallization of LA and Adjuvant Mixtures in Cerebrospinal Fluid

  NCT07442929· Medical University Innsbruck· Source

• Completed

  A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

  NCT06312020· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A Study of TAK-861 in People With Narcolepsy Type 1

  NCT06505031· Phase 3· Takeda· Source

• Completed

  A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB310 in Patients with Active, Mild to Moderate Ulcerative Colitis (COMPOSER-1)

  2023-507376-50-00· Phase 1· Microbiotica Limited· Source

• Completed

  A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

  NCT06582264· Phase 1· Microbiotica Ltd· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Hoffmann-La Roche· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source

• Completed

  A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

  NCT05870748· Phase 2· Sutro Biopharma Inc.· Source

• Completed

  A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  2023-509472-42-00· Phase 3· Celgene International II S.a.r.l.· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06212999· Phase 3· Incyte Corporation· Source

• Terminated

  A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

  NCT06082843· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

  NCT05748483· Phase 3· AbbVie· Source

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Kartos Therapeutics Inc.· Source

• Completed

  Clinical trial of MK-7648A in adults and children with skin cancer

  NCT05665595· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

  NCT05911360· Phase 3· ViiV Healthcare· Source

• Completed

  A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)

  NCT05878938· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma

  2022-501463-40-01· Phase 3· Servier Affaires Medicales· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Withdrawn

  Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia

  NCT03761511· Phase 2· RWTH Aachen University· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Insel Gruppe AG, University Hospital Bern· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Active, not recruiting

  GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

  NCT05686551· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT05620823· Phase 3· Incyte Corporation· Source

• Completed

  Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

  NCT05092360· Phase 3· Mural Oncology Inc.· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Active, not recruiting

  Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

  NCT05331183· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

  NCT05518123· Phase 4· Pfizer· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

  NCT05509400· Phase 4· Pfizer· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)

  NCT05111626· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382299· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

  NCT05338970· Phase 3· Daiichi Sankyo· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

  NCT05358717· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

  NCT05416307· Phase 2/3· Electra Therapeutics Inc.· Source

• Terminated

  A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

  NCT05161481· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Biogen· Source

• Completed

  ​Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)​

  NCT05226598· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

  NCT05217927· Phase 4· Pfizer· Source

• Completed

  Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis

  NCT04987307· Phase 2· Amgen Inc.· Source

• Completed

  MR-Spectroscopy: Investigating neurochemical changes in brain metabolism in migraineurs before and after CGRP-Antibody treatment – a randomized, controlled, open-label trial.

  2024-517079-19-00· Phase 4· Medizinische Universitaet Innsbruck· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

Showing 50 of 101.

Conditions

Diseases this institution publishes on or runs trials for.

• Parkinson disease55 works · 14 trials
• Bladder cancer38 works · 6 trials
• Multiple sclerosis32 works · 6 trials
• Multiple system atrophy21 works · 6 trials
• Endometrial cancer19 works · 11 trials
• Dystonia15 works · 0 trials
• ANCA-associated vasculitis12 works · 2 trials
• Lewy body dementia8 works · 0 trials
• Huntington's disease8 works · 4 trials
• Neuromyelitis optica (NMOSD)8 works · 0 trials
• Friedreich ataxia7 works · 5 trials
• Brain aneurysm6 works · 0 trials
• Restless legs syndrome5 works · 2 trials
• Iron deficiency anaemia4 works · 0 trials
• Polycystic kidney disease4 works · 2 trials
• Narcolepsy4 works · 4 trials
• Nephrotic syndrome4 works · 0 trials
• Sjögren's disease3 works · 1 trial
• Polymyalgia rheumatica3 works · 0 trials
• Fabry disease3 works · 0 trials